Made available in DSpace on 2014-12-17T14:13:41Z (GMT). No. of bitstreams: 1 NednaldoDS_TESE.pdf: 2321205 bytes, checksum: c08caa8155a3fd7b840048363939c371 (MD5) Previous issue date: 2012-03-19 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico / Sulfated polysaccharides (SP) are widely distributed in animals and seaweeds tissues. These polymers have been studied in light of their important pharmacological activities, such as anticoagulant, antioxidant, antitumoral, anti-inflammatory, and antiviral properties. On other hand, SP potential to synthesize biomaterials like as nanoparticules has not yet been explored. In addition, to date, SP have only been found in six plants and all inhabit saline environments. However, the SP pharmacological plant activities have not been carrying out. Furthermore, there are no reports of SP in freshwater plants. Thus, do SP from marine plants show pharmacological activity? Do freshwater plants actually synthesize SP? Is it possible to synthesize nanoparticles using SP from seaweed? In order to understand this question, this Thesis was divided into tree chapters. In the first chapter a sulfated polysaccharide (SPSG) was successfully isolated from marine plant Halodule wrightii. The data presented here showed that the SPSG is a 11 kDa sulfated heterogalactan contains glucose and xylose. Several assays suggested that the SPSG possessed remarkable antioxidant properties in different in vitro assays and an outstanding anticoagulant activity 2.5-fold higher than that of heparin Clexane? in the aPTT test; in the next chapter using different tools such as chemical and histological analyses, energy-dispersive X-ray analysis (EDXA), gel electrophoresis and infra-red spectroscopy we confirm the presence of sulfated polysaccharides in freshwater plants for the first time. Moreover, we also demonstrate that SP extracted from E. crassipes root has potential as an anticoagulant compound; and in last chapter a fucan, a sulfated polysaccharide, extracted from the brown seaweed was chemically modified by grafting hexadecylamine to the polymer hydrophilic backbone. The resulting modified material (SNFuc) formed nanosized particles. The degree of substitution for hydrophobic chains of 1H NMR was approximately 93%. SNFfuc-TBa125 in aqueous media had a mean diameter of 123 nm and zeta potential of -38.3 ? 0.74 mV, measured bydynamic light scattering. Tumor-cell (HepG2, 786, H-S5) proliferation was inhibited by 2.0 43.7% at SNFuc concentrations of 0.05 0.5 mg/ mL and RAEC non-tumor cell line proliferation displayed inhibition of 8.0 22.0%. On the other hand, nanogel improved CHO and RAW non-tumor cell line proliferation in the same concentration range. Flow cytometric analysis revealed that this fucan nanogel inhibited 786 cell proliferation through caspase and caspaseindependent mechanisms. In addition, SNFuc blocks 786 cell passages in the S and G2-M phases of the cell cycle / Os polissacar?deos sulfatados (PS) s?o amplamente distribu?dos em animais e tecidos de algas. Estes pol?meros t?m sido estudados em fun??o da import?ncia de suas atividades farmacol?gicas, tais como: anticoagulante, antioxidante, antitumoral, anti-inflamat?ria e as propriedades antivirais. Contudo, o potencial dos PS para sintetizar biomateriais, tais como nanopart?culas, ainda ? pouco explorado. At? ent?o, os PS s? foram encontrados em seis plantas e todas habitam ambientes salino. N?o havendo relatos de PS em plantas de ?gua doce. O que nos levou aos seguintes questionamentos: Os PS extraidos de vegetais marinhos n?o apresentam atividades farmacol?gicas? Os vegetais de ?gua doce realmente sintetizam PS? ? poss?vel sintetizar nanopart?culas utilizando PS a partir de algas marinhas? Para melhor entender as quest?es, esta tese foi dividida em tr?s cap?tulos. No primeiro cap?tulo, um polissacar?deo sulfatado (SPSG) foi isolado a partir de um vegetal marinho Halodule wrightii. Os dados aqui apresentados mostram que o SPSG ? uma heterogalactana sulfatada de 11 kDa constituida de glucose e xilose. Os ensaios realizados sugerem que o SPSG possue propriedades antioxidantes not?veis em diferentes ensaios in vitro e uma excelente actividade anticoagulante de 2,5 vezes mais elevadas do que a de heparina Clexane ? no teste APTT. No cap?tulo seguinte, utilizando ferramentas diferentes, tais como an?lises qu?micas e histol?gicas, an?lise de dispers?o de raios-X (EDXA), eletroforese em gel e espectroscopia de infra-vermelho,confirmamos, em primeira m?o, a presen?a de polissacar?deos sulfatados em vegetais de ?gua doce. Al?m de demonstrarmos que o PS extra?do a partir da raiz de E. crassipes tem potencial como um composto anticoagulante.No ?ltimo cap?tulo uma fucana, um polissac?rido sulfatado, extra?do a partir de uma alga marrom, foi quimicamente modificada por adi??o de hexadecilamina ? cadeia principal do pol?mero hidrof?lico. O material resultante (SNFuc) forneceu part?culas nanom?tricas. O grau de substitui??o para as cadeias hidrof?bicas de 1H RMN foi de aproximadamente 93%. SNFuc em meios aquosos tinha um di?metro m?dio de 123 nm e potencial zeta de -38,3 ? 0,74 mV. Os ensaios com c?lulas tumorais (HepG2, 786, H-S5) demonstrou a ocorr?ncia de uma inibi??o que variou de 2,0-43,7% em concentra??es diferentes de SNFuc (0,05-0,5 mg / mL) resultado semelhante foi obtido com a RAEC monstrando uma inibi??o entre 8,0-22,0%. Por outro lado, o nanogel estimulou a prolifera??o de linhagens celulares n?o tumorais como CHO e RAW nas mesmas concentra??es. An?lise por citometria de fluxo revelou que este nanogel de fucana inibiu a prolifera??o celular de 786 por mecanismos dependentes e independentes de caspases. Al?m disso, bloqueou a passagens da c?lula 786 na fase S e G2-M do ciclo celular / 2020-01-01

Made available in DSpace on 2014-07-29T16:11:50Z (GMT). No. of bitstreams: 1 Dissertacao Laura Maia Mairink Nassau.pdf: 2613768 bytes, checksum: d2e4321ca6a3e7930e1a7f57b3099a11 (MD5) Previous issue date: 2010-09-15 / Thromboembolic disorders produce the majority of diseases affecting the heart, and are the third leading cause of death worldwide. Venous thromboembolism is a thromboembolic disorder that occurs in the venous circulation, is a disease of high prevalence and remains a major cause of morbidity and mortality in hospitalized patients undergoing major surgery, the fact that affect patients from the very young, disease free prior to the more elderly mean that it is a problem with major socioeconomic burden by as much as by absenteeism in hospital patients in productive age. This describes the planning and synthesis of intermediates for the collection of new derivatives guanidine drawn from the infestina-4, protein extracted from the stomach Barber Triatoma infestans, with potent inhibitory activity of factor XII. Factor XII acts of direct and indirect enzymatic cascades in four of our body and has an important contribution to the formation of pathological vascular thrombi. The previous study of molecular modeling justified based planning in the structural and the electrostatic infestin. Thus it is concluded that the synthesis of intermediates 25-28, were getting adequate yields of 88.0 and 92.0% for compounds 25 and 26 and 71.4 and 65.0% for compounds 27 and 28 respectively. / As desordens tromboembólicas geram a maioria das doenças que acometem o coração, e são a terceira causa de morte mundial. O tromboembolismo venoso é uma desordem tromboembólica que ocorre na circulação venosa, é uma enfermidade de alta prevalência e continua sendo uma causa importante de morbimortalidade em pacientes hospitalizados e submetidos a cirurgias de grande porte, o fato de afetar pacientes desde os mais jovens, sem doenças prévias, até os mais idosos fazem com que ela constitua um problema sócio-econômico com grandes ônus tanto pelas internações quanto pelo absenteísmo em pacientes em idade produtiva. Este trabalho descreve o planejamento e a síntese de intermediários para obtenção de novos derivados guanidínicos desenhados a partir da infestina-4, proteína extraída do estômago do barbeiro Triatoma infestans, com potente atividade inibitória do fator XII. O fator XII atua de forma direta e indireta em quatro cascatas enzimáticas do nosso organismo e possui importante contribuição na formação patológica de trombos vasculares. O estudo prévio de modelagem molecular justificou o planejamento baseado nas características estruturais e eletrostáticas da infestina. Desta forma, conclui-se que a síntese dos intermediários 25-28 foram adequadas obtendo rendimentos de 88,0 e 92,0% para os compostos 25 e 26 e de 71,4 e 65,0% para os compostos 27 e 28, respectivamente.

For the successful food intake by organisms that feed on blood is essentials presence of antihaemostatic molecules such as vasodilators, anticoagulant molecules and apyrases., Although members of family Diplozoidae (Heteronchoinea) are blood-feeding parasites on the gills of the fish, these molecules, that could disrupt host hemostasis, have not yet been identified. Thus, the aim of this study was to find molecules with potential anticoagulant activity in homogenates of whole worm bodies and excretory/secretory products of the members of family Diplozoidae. Furthermore perform bioinformatics analysis of sequences obtained from transcriptom project of Eudiplozoon nipponicum (Heteronchoinea: Diplozoidae) and selected proteins (protein domain) then expressed in a recombinant form. We tested inhibitory activity in excretory-secretory products and homogenates of members family Diplozoidae towards coagulation factors IIa and Xa and their specific fluorogenic with 4 negative and 1 positive results. From the results of two transcriptome analysis we discovered three protein families of potential anticoagulants - annexins, serpins and Kunitz-domain proteins. For further analyses we focused on the Kunitz protein family. These proteins contain one or more structurally related active domains which are able to...

L’apport en vitamine K a été identifié comme un facteur influençant la stabilité de l’anticoagulothérapie à long terme. Des études cliniques ont montré que les patients recevant un supplément de vitamine K (100 à 150 μg/jour) bénéficiaient d’une amélioration de la stabilité de l’anticoagulothérapie. Dans le but de vérifier si un effet bénéfique similaire peut être obtenu grâce à une augmentation de l’apport de vitamine K à partir de la diète, un essai contrôlé randomisé de 24 semaines a été mené. Les patients randomisés dans le groupe d’intervention ont participé à des ateliers proposant des recommandations nutritionnelles afin d’augmenter leur apport en vitamine K d’au moins 150 μg/jour. Les patients du groupe contrôle ont participé à des ateliers distincts recommandant une alimentation équilibrée. La stabilité de l’anticoagulothérapie a été définie par le pourcentage de temps passé dans la fenêtre thérapeutique (TTR≥70%) entre les semaines 4 et 24. L’analyse basée sur l’intention de traitement a montré que le pourcentage des participants qui répondaient aux critères de stabilité à l’anticoagulation étaient 44,4% et 27,3% pour le groupe d’intervention et le groupe contrôle, respectivement (p=0,22). L’analyse conforme au protocole a accentué la différence entre les groupes intervention et contrôle (52,2% et 27,3%, respectivement (p=0,088)). Les deux analyses ont montré que l’apport moyen de vitamine K calculé entre les semaines 6 et 24 était supérieur dans le groupe d’intervention par rapport au groupe contrôle (p=0,001). Cette étude tend à appuyer l’hypothèse selon laquelle un apport quotidien élevé de vitamine K améliore la stabilité de l’anticoagulothérapie. / Vitamin K intake has emerged as an important factor in influencing the stability of long-term anticoagulation therapy. Clinical trials have shown that patients receiving a vitamin K supplement (100 - 150 μg/d) present improvements in the stability of their anticoagulant therapy. Thus, a 24-week randomized controlled trial was conducted to verify whether similar beneficial effects could be achieved by increasing daily vitamin K intake through the diet. Patients randomly assigned to the intervention group attended workshops that provided dietary counsel to increase their vitamin K intake by ≥ 150 μg/day. Patients in the control group participated in distinct workshops providing general advice on a balanced diet. The stability of anticoagulation therapy was defined as the percentage of time spent in the therapeutic range (TTR ≥ 70%) during weeks 4 through 24 of the experimental period. Intention to treat analysis showed that the percentage of participants who benefited from an improvement in the stability of anticoagulation therapy was greater in the intervention group than the control group (44.4% vs 27.3% respectively; p=0.22). Per protocol analysis accentuated the difference between groups i.e. 52.2% vs 27.3% in intervention and control group respectively (p=0.088). Both analyses showed that the mean vitamin K intake calculated during weeks 6 through 24 was higher in the intervention than in the control group (p=0.001). The study tends to support the hypothesis that a high daily vitamin K intake improves the anticoagulation stability of warfarin-treated patients.

Venous thromboembolism (VTE), defined as deep vein thrombosis and/or pulmonary embolism is the second leading cause of mortality in cancer patients, second only to cancer itself. A number of reports suggest that circulating extracellular vesicles (EVs) may be increased in cancer patients with VTE. The aim of this study was to examine circulating EVs in high-risk ambulatory cancer patients, determine if levels are associated with hematological outcomes (VTE, major bleeding event), and to assess the impact of prophylactic antithrombotic therapy (Apixaban). We hypothesized that elevated levels of circulating large EVs will be predictive of cancer associated VTE and/or bleeding events and that treatment with Apixaban will reduce EV levels and incidence of cancer VTE. Plasma samples from patients at baseline, and 90-days follow-up from the Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer patients (AVERT) trial were investigated. Total EVs were quantified by their pro-coagulant activity using the Zymuphen MP-Activity kit. Platelet, endothelial and tissue-factor EV levels were quantified by flow cytometry. We observed that circulating EVs exhibited significant associations with sex, age, and cancer type, however we did not observe any relationships with clinical outcomes. Thus, it appears that circulating EVs may not have a role in risk stratification for VTE in in high-risk ambulatory cancer patients.

Background: Warfarin is an anticoagulant that is used for the prophylactic and therapeutic treatment for a wide range of thrombo-embolic disorders. The prescribing and monitoring of warfarin therapy is challenging due to the fact that warfarin exhibits numerous interactions with other drugs and a variety of factors that influence the dosing of warfarin. Objective: The general objective of this study was to investigate the prevalence of drugs prescribed with warfarin that may have a potential drug-drug interaction (DDI) with warfarin. Methods: This was a cross-sectional, observational or qualitative study that was conducted on medicine claims data of a pharmaceutical benefit management company for patients receiving warfarin therapy for a six year period, ranging from 1 January 2005 to 31 December 2010. Drug products that were co-prescribed with warfarin were also identified from the medicine claims database. The total number of prescriptions for all drug products during the study period were analysed and compared to the warfarin dataset. This was done by means of the SAS 9.1® computer package (SAS Institute, 2004). The total number of prescriptions and medicine items claimed from the database during the study period were respectively 49 523 818 and 118 305 941. Potential DDls between warfarin and coprescribed drugs were identified and classified according to a clinically significant rating. The clinically significance ratings of potential DDls are described in three degrees of severity, identified as major, moderate and minor (Tatro, 2011 :xiv). Results: The database consisted of 427 238 warfarin prescriptions and 427 744 warfarin medicine items, which represented 0.9% of the total number of prescriptions and 0.4% of total number of medicine items. The total number of patients who claimed warfarin prescriptions through the database represented 0.9% (n=68 575) of the total number of patients who claimed prescriptions in the total database (2005-2010). General practitioners prescribed the highest frequency of warfarin medicine items, representing 58.3% (n=249 202) of the total number prescribed. The age group that claimed the highest frequency of warfarin prescriptions (n=327 592, 76.6%) and the highest frequency of warfarin medicine items (n=327 984, 76.7%) was age group 4 (consisting of patients 59 years and older). The distribution between females and males regarding warfarin prescriptions claimed (n=205 999, 48.2%; n=221 117, 51.8%) and warfarin medicine items claimed (n=206 232, 48.2%; n=221 390, 51.8%) were almost equal. General practitioners prescribed the highest average PDD (7.01 mg ± 9.86 mg) of warfarin medicine items. Paediatric cardiologists prescribed the lowest average PDD (4.61 mg ± 1.29 mg) of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDD between general practitioners and paediatric cardiologists. The average PDD of warfarin medicine items between females (6.60 mg ± 9.06 mg) and males (6.74 mg± 8.41 mg) was almost equal. The age group who was prescribed the highest average PDD was age group 2 (consisting of patients 20 years to 39 years old) (7.42 mg± 7.42 mg). Age group 4 (consisting of patients 59 years and older) (6.50 mg± 8.90 mg) was prescribed the lowest average PDD of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDDs of warfarin medicine items between these two age groups. The results revealed that drugs with a significance rating (SR) of 1 (n=155 066, 43.3%), 2 (n=30128, 8.4%), 4 (n=137144, 38.3%), and 5 (n=36144, 10.1%) were co-prescribed with warfarin in the six year study period. The five drugs that was co-prescribed with warfarin most frequently was aspirin (n=48 903, 13.6%), thyroxine (n=33 954, 9.5%), amiodarone (n=25 056, 7.0%), simvastatin (n=19 070, 5.3%) and celecoxib (n=10 794, 3.0%). These five drugs have a SR of 1. Conclusions: This study showed that the top five drugs most frequently prescribed with warfarin are aspirin, thyroxine, amiodarone, simvastatin and celecoxib. These drugs can potentially interact with warfarin. The potential interactions of these drugs are rated with a significance rating of 1. This concludes that drugs that can potentially cause life threatening effects and permanent damage are commonly co-prescribed with warfarin. Clinical data concerning the INR or PT must be obtained in order to evaluate whether or not warfarin therapy is changed when a potentially interacting drug is co-prescribed. The age of the patients as well as the duration of warfarin treatment should also be obtained in order to assess whether warfarin treatment is changed with the progression of age. / MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2013

Background: Warfarin is an anticoagulant that is used for the prophylactic and therapeutic treatment for a wide range of thrombo-embolic disorders. The prescribing and monitoring of warfarin therapy is challenging due to the fact that warfarin exhibits numerous interactions with other drugs and a variety of factors that influence the dosing of warfarin. Objective: The general objective of this study was to investigate the prevalence of drugs prescribed with warfarin that may have a potential drug-drug interaction (DDI) with warfarin. Methods: This was a cross-sectional, observational or qualitative study that was conducted on medicine claims data of a pharmaceutical benefit management company for patients receiving warfarin therapy for a six year period, ranging from 1 January 2005 to 31 December 2010. Drug products that were co-prescribed with warfarin were also identified from the medicine claims database. The total number of prescriptions for all drug products during the study period were analysed and compared to the warfarin dataset. This was done by means of the SAS 9.1® computer package (SAS Institute, 2004). The total number of prescriptions and medicine items claimed from the database during the study period were respectively 49 523 818 and 118 305 941. Potential DDls between warfarin and coprescribed drugs were identified and classified according to a clinically significant rating. The clinically significance ratings of potential DDls are described in three degrees of severity, identified as major, moderate and minor (Tatro, 2011 :xiv). Results: The database consisted of 427 238 warfarin prescriptions and 427 744 warfarin medicine items, which represented 0.9% of the total number of prescriptions and 0.4% of total number of medicine items. The total number of patients who claimed warfarin prescriptions through the database represented 0.9% (n=68 575) of the total number of patients who claimed prescriptions in the total database (2005-2010). General practitioners prescribed the highest frequency of warfarin medicine items, representing 58.3% (n=249 202) of the total number prescribed. The age group that claimed the highest frequency of warfarin prescriptions (n=327 592, 76.6%) and the highest frequency of warfarin medicine items (n=327 984, 76.7%) was age group 4 (consisting of patients 59 years and older). The distribution between females and males regarding warfarin prescriptions claimed (n=205 999, 48.2%; n=221 117, 51.8%) and warfarin medicine items claimed (n=206 232, 48.2%; n=221 390, 51.8%) were almost equal. General practitioners prescribed the highest average PDD (7.01 mg ± 9.86 mg) of warfarin medicine items. Paediatric cardiologists prescribed the lowest average PDD (4.61 mg ± 1.29 mg) of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDD between general practitioners and paediatric cardiologists. The average PDD of warfarin medicine items between females (6.60 mg ± 9.06 mg) and males (6.74 mg± 8.41 mg) was almost equal. The age group who was prescribed the highest average PDD was age group 2 (consisting of patients 20 years to 39 years old) (7.42 mg± 7.42 mg). Age group 4 (consisting of patients 59 years and older) (6.50 mg± 8.90 mg) was prescribed the lowest average PDD of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDDs of warfarin medicine items between these two age groups. The results revealed that drugs with a significance rating (SR) of 1 (n=155 066, 43.3%), 2 (n=30128, 8.4%), 4 (n=137144, 38.3%), and 5 (n=36144, 10.1%) were co-prescribed with warfarin in the six year study period. The five drugs that was co-prescribed with warfarin most frequently was aspirin (n=48 903, 13.6%), thyroxine (n=33 954, 9.5%), amiodarone (n=25 056, 7.0%), simvastatin (n=19 070, 5.3%) and celecoxib (n=10 794, 3.0%). These five drugs have a SR of 1. Conclusions: This study showed that the top five drugs most frequently prescribed with warfarin are aspirin, thyroxine, amiodarone, simvastatin and celecoxib. These drugs can potentially interact with warfarin. The potential interactions of these drugs are rated with a significance rating of 1. This concludes that drugs that can potentially cause life threatening effects and permanent damage are commonly co-prescribed with warfarin. Clinical data concerning the INR or PT must be obtained in order to evaluate whether or not warfarin therapy is changed when a potentially interacting drug is co-prescribed. The age of the patients as well as the duration of warfarin treatment should also be obtained in order to assess whether warfarin treatment is changed with the progression of age. / MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2013

Diss. Stockholm : Handelshögskolan, 2006 S. 1-125 : 4 uppsatser

Made available in DSpace on 2014-12-17T14:03:32Z (GMT). No. of bitstreams: 1 RaniereFMS.pdf: 3115798 bytes, checksum: 664aaedacd292e8b8c2d08a15e193378 (MD5) Previous issue date: 2010-02-25 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico / The corn cob is an agricultural by-product still little used, this in part due to the low knowledge of the biotechnological potential of their molecules. Xylan from corn cobs (XSM) is a polysaccharide present in greater quantity in the structure of plant and its biotechnology potential is little known. This study aimed to the extraction, chemical characterization and evaluation of biological activities of xylan from corn cobs. To this end, corncobs were cleaned, cut, dried and crushed, resulting in flour. This was subjected to a methodology that combines the use of alkaline conditions with waves of ultrasound. After methanol precipitation, centrifugation and drying was obtained a yield of 40% (g/g flour). Chemical analysis indicated a high percentage of polysaccharides in the sample (60%) and low contamination by protein (0.4%) and phenolic compounds (> 0.01%). Analysis of monosaccharide composition indicated the presence of xylose:glucose:arabinose:galactose:mannose:glucuronic acid in a molar ratio 50:20:15:10:2.5:2.5. The presence of xylan in the sample was confirmed by nuclear magnetic resonance (?H and ??C) and infrared spectroscopy (IR). Tests were conducted to evaluate the antioxidant potential of XSM. This showed a total antioxidant capacity of 48.45 EAA/g sample. However, did not show scavenging activity of superoxide and hydroxyl radical and also reducing power. But, showing a high capacity chelating iron ions with 70% with about 2 mg/mL. The ability to XSM to influence cell proliferation in culture was also evaluated. This polymer did not influence the proliferation of normal fibroblast cells (3T3), however, decreased the rate of proliferation of tumor cells (HeLa) in a dose-dependent, reaching an inhibition of about 50% with a concentration around 2 mg/mL. Analyzing proteins related to cell death, by immunoblotting, XSM increases the amount of Bax, Bcl-2 decrease, increase cytochrome c and AIF, and reduce pro-caspase-3, indicating the induction of cell death induced apoptosis dependent and independent of caspase. XSM did not show anticoagulant activity in the PT test. However, the test of activated partial thromboplastin time (aPTT), XSM increased clotting time at about 5 times with 600 ?g of sample compared with the negative control. The presence of sulfate on the XSM was discarded by agarose gel electrophoresis and IR. After carboxyl-reduction of XSM the anticoagulant activity decreased dramatically. The data of this study demonstrate that XSM has potential as antioxidant, antiproliferative and anticoagulant compound. Future studies to characterize these activities of XSM will help to increase knowledge about this molecule extracted from corn and allow their use in functional foods, pharmaceuticals and chemical industries. / O sabugo de milho ? um subproduto agr?cola ainda pouco utilizado, isto se deve em parte ao baixo conhecimento do potencial biotecnol?gico de suas biomol?culas. Xilana de sabugo de milho (XSM) ? um polissacar?deo presente em maior quantidade na estrutura do vegetal e seu potencial biotecnol?gico ? pouco conhecido. Este trabalho teve como objetivo a extra??o, caracteriza??o qu?mica e avalia??o de atividades biol?gicas de XSM. Sabugos de milho foram limpos, cortados, desidratados e triturados, dando origem a uma farinha. Esta foi submetida a uma metodologia que combina o uso de meio alcalino com ondas de ultra-som. Ap?s precipita??o metan?lica, centrifuga??o e secagem obteve-se um rendimento de 40% (g/g de farinha). An?lises qu?micas indicaram um alto percentual de polissacar?deos na amostra (60%) e baixa contamina??o por prote?nas (0.4%) e compostos fen?licos (>0.01%). An?lises da composi??o monossacar?dica por cromatografia em papel e por cromatografia l?quida de alta performance (CLAE) indicaram a presen?a de xilose:glicose:arabinose:galactose:manose:?cido glucur?nico em uma propor??o molar de 50:20:15:10:2,5:2,5. A presen?a de xilana na amostra foi confirmada por resson?ncia magn?tica nuclear (13C e 1H) e por espectroscopia de infravermelho (IR). Testes foram realizados para avalia??o do potencial antioxidante de XSM. Esta mostrou uma capacidade antioxidante total de 48.45 EAA/g de amostra. Contudo, a mesma n?o mostrou atividade sequestradora de super?xido, radical hidroxila bem como poder redutor. Em contra partida, apresentou 70% de atividade quelante de ?ons de ferro na concentra??o de 2 mg/mL. A capacidade de XSM em influenciar a prolifera??o celular em cultura tamb?m foi avaliada. Este polissacar?deo n?o influenciou a prolifera??o de c?lulas fibrobl?sticas normais (3T3), entretanto, diminuiu a taxa de prolifera??o de c?lulas tumorais (HeLa) de maneira dose-dependente, chegando a uma inibi??o de aproximadamente 50% com concentra??o em torno de 2 mg/mL. Analisando prote?nas relacionadas ? morte celular, atrav?s de immunoblotting, XSM aumenta a quantidade de Bax, citocromo c e AIF e diminui Bcl-2 e procaspase- 3, indicando a indu??o de morte celular por apoptose dependente e independente de caspase. XSM n?o apresentou atividade anticoagulante pelo teste de PT. Todavia, no teste de tempo de tromboplastina parcial ativada (aPTT), XSM aumentou o tempo de coagula??o em cerca de 5 vezes utilizando 600 ?g de amostra, quando comparadas com o controle negativo. A presen?a de sulfato ligado a XSM foi descartada por eletroforese em gel de agarose e por IR. Ap?s carboxirredu??o de XSM a atividade anticoagulante diminuiu drasticamente. Os dados deste trabalho demonstram que XSM apresenta potencial como composto antioxidante, antiproliferativo e anticoagulante. Estudos futuros de caracteriza??o dessas atividades do XSM contribuir?o para aumentar o conhecimento sobre esta mol?cula extra?da de milho e permitir?o a sua utiliza??o em alimentos funcionais, produtos farmac?uticos e ind?strias qu?micas.

Made available in DSpace on 2014-12-17T14:03:38Z (GMT). No. of bitstreams: 1 MoniqueGCFA_DISSERT_PARCIAL.pdf: 1765775 bytes, checksum: 3815c2c3560cb6ce59df27ea29b474ca (MD5) Previous issue date: 2011-07-18 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico / Marine algae are one of the major sources of biologic compounds. In extracellular matrix of these organisms there are sulfated polysaccharides that functions as structural components and provides protection against dehydration. The fraction 1.0 (F1.0) rich in sulfated galactans obtained from red seaweed Hypnea musciformis was physicochemical characterized and evaluated for pharmacologic activity through antioxidant activity, cytotoxic action on erythrocytes, anticoagulant, stimulatory action under antithrombotic heparan sulfate synthesis and their effects on cell proliferation and cycle cell progression. The main components of F1.0 were carbohydrates (49.70 ? 0.10%) and sulfate (44.59 ? 0.015%), presenting phenolic compounds (4.79 ? 0.016%) and low protein contamination (0.92 ? 0.001%). Fraction 1.0 showed polidisperse profile and signs in infrared analysis in 1262, 1074 and 930, 900 and 850 attributed to sulfate esters S=O bond, presence of a 3,6- anidrogalactose C-O bond, non-sulfated ?-D-galactose and a C-O-SO4 bond in galactose C4, respectively. The fraction rich in sulfated galactans exhibited strong antioxidant action under lipid peroxidation assay with IC50 of 0.003 mg/mL. Besides the inhibition of hemolysis induced by H2O2 in erythrocytes treated with F1.0, this fraction did not promote significant cytotoxity under erythrocytes membranes. F1.0 exhibited low anticoagulant activity causing moderate direct inhibition of enzimatic activity of thrombin. This fraction promoted stimulation around of 4.6 times on this synthesis of heparan sulfate (HS) by rabbit aortic endothelial cells (RAEC) in culture when was compared with non treated cells. The fraction of this algae displayed antiproliferative action under RAEC cells causing incresing on cell number on S fase, blocking the cycle cell progression. Thus F1.0 presented cytostatic and no cytotoxic action under this cell lineage. These results suggest that F1.0 from H. musciformis have antioxidant potential which is a great effect for a compound used as food and in food industry which could be an alternative to food industry to prevent quality decay of lipid containing food due to lipid peroxidation. These polysaccharides prevent the lipid peroxidation once the fraction in study exhibited strong inhibitory action of this process. Furthermore that F1.0 present strong antithrombotic action promoting the stimulation of antithrombotic HS synthesis by endothelial cells, being important for thrombosis preventing, by its inhibitory action under reactive oxygen species (ROS) in some in vitro methods, being involved in promotion of hypercoagulability state. / Algas marinhas s?o uma das principais fontes de compostos biologicamente ativos. Na matriz extracelular desses organismos existem os polissacar?deos sulfatados que funcionam como componente estrutural prevenindo-a contra desidrata??o. A fra??o 1,0 (F1,0) rica em galactanas sulfatadas obtida da alga vermelha Hypnea musciformis foi caracterizada fisicoquimicamente e avaliada quanto a atividade farmacol?gica por meio de ensaios de atividade antioxidante, a??o citot?xica sobre hem?cias, atividade anticoagulante, a??o estimulat?ria sobre a s?ntese de heparam sulfato antitromb?tico e seus efeitos na prolifera??o e progress?o do ciclo celular. Os principais componentes da F1,0 foram carboidratos (49,70 ? 0,10%) e sulfato (44,59 ? 0,015%), apresentando compostos fen?licos (4,79 ? 0,016%) e baixa contamina??o prot?ica (0,92 ? 0,001%). F1,0 mostrou perfil polidisperso e sinais na an?lise de infravermelho em 1262, 1074 e 930, 900 e 850 cm-1 atribu?dos a liga??es S=O de ?steres de sulfato, presen?a de liga??o C-O de 3,6-anidrogalactose, ?-D-galactose n?o sulfatada e liga??o C-O-SO4 no C4 da galactose, respectivamente. A fra??o rica em galactanas sulfatadas exibiu forte a??o antioxidante sobre o ensaio de peroxida??o lip?dica com IC50 de 0,003 mg/mL. Al?m da alta inibi??o da hem?lise induzida por H2O2 em hem?cias humanas tratadas com F1,0, esta fra??o n?o promoveu citotoxicidade significativa sobre a membrana de hem?cias. F1,0 exibiu baixa atividade anticoagulante, causando moderada inibi??o direta da atividade enzim?tica da trombina. Esta fra??o promoveu estimula??o de cerca de 4,6 vezes na s?ntese de heparam sulfato (HS) pelas c?lulas endoteliais da aorta de coelho (RAEC), em cultura, quando comparadas com as c?lulas n?o tratadas com F1,0. A fra??o dessa alga mostrou atividade antiproliferativa sobre as c?lulas RAEC, causando aumento no n?mero de c?lulas na fase S, impedindo a progress?o do ciclo celular. Assim, F1,0 apresentou a??o citost?tica e n?o citot?xica sobre esta linhagem celular. Esses resultados sugerem que F1,0 de H. musciformis tem potencial antioxidante, efeito importante para um composto utilizado como alimento e na ind?stria aliment?cia, podendo ser uma alternativa na ind?stria aliment?cia para a preven??o do decaimento da qualidade dos alimentos contendo lip?dio devido a peroxida??o lip?dica, uma vez que a fra??o em estudo exibiu forte a??o inibit?ria sobre a peroxida??o lip?dica. Al?m disso F1,0 apresenta forte a??o antitromb?tica promovendo a estimula??o da s?ntese de HS antitromb?tico pelas c?lulas endoteliais, sendo ?til na preven??o da trombose, devido tamb?m a sua a??o inibit?ria sobre as esp?cies reativas do oxig?nio (ROS) em alguns sistemas in vitro, estando envolvidos na promo??o de estado de hipercoagulabilidade.